| Autor: |
Tanaka M; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimomura A; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Terakado H; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Shimizu C; Maho Tanaka, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; Hiroyuki Terakado, RPh, Department of Pharmacy, National Center for Global Health and Medicine, Tokyo, Japan; and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan. |
| Abstrakt: |
Competing Interests: Akihiko ShimomuraHonoraria: Chugai Pharma, AstraZeneca, Pfizer, Novartis, Eisai, Lilly, Daiichi Sankyo/UCB Japan, Kyowa Kirin InternationalConsulting or Advisory Role: Lilly Japan, AstraZeneca, PfizerResearch Funding: Chugai Pharma, AstraZeneca, Daiichi Sankyo, Mochida Pharmaceutical Co Ltd, Taiho Pharmaceutical Chikako ShimizuHonoraria: AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Taiho Pharmaceutical, PfizerConsulting or Advisory Role: AstraZeneca, MSDResearch Funding: LillyNo other potential conflicts of interest were reported. |
